November 25, 2017 5:13 AM ET

Diversified Consumer Services

Company Overview of Cornell University

Company Overview

Cornell University is an educational institution that offers undergraduate majors, graduate, undergraduate and advanced degrees, and continuing education and outreach programs. It has seven undergraduate colleges; a graduate school; professional-degree schools in business management, medicine, law, and veterinary medicine; and affiliated faculty units. Cornell University was founded in 1865 and is based in Ithaca, New York.

144 East Avenue

Day Hall Lobby

Ithaca, NY 14850

United States

Founded in 1865

15,590 Employees





Key Executives for Cornell University

Chief of Cornell University Police, Interim VP of Risk Mgmt & Public Safety and Assoc. VP
Natural Resource Team Coordinator
Director Emeritus of National Astronomy and Ionosphere Center (NAIC)
Senior Vice Provost - Research, VP for Technology Transfer, Intellectual Property & Research Policy
Director of Arecibo Observatory
Compensation as of Fiscal Year 2017.

Cornell University Key Developments

Cornell University Presents at Food and Nutrition Conference & Expo, Oct-21-2017

Cornell University Presents at Food and Nutrition Conference & Expo, Oct-21-2017 . Venue: Chicago, Illinois, United States. Speakers: Kathleen Rasmussen, the Nancy Schlegel Meinig Professor of Maternal and Child Nutrition, Marie Caudill, Professor, Patsy M Brannon, Professor.

Cornell University Presents at Strata + Hadoop World, Sep-26-2017 10:00 AM

Cornell University Presents at Strata + Hadoop World, Sep-26-2017 10:00 AM. Venue: Javits Convention Center, 655 W 34th Street, New York, New York, United States. Speakers: Madeleine Udell.

Recro Pharma, Inc. Enters into License Agreement with Cornell University

On June 30, 2017, Recro Pharma Inc. entered into a license agreement with Cornell University, pursuant to which Cornell granted the Company a worldwide, exclusive, sublicensable, royalty-bearing license in Cornell's patents and other intellectual property relating to an intermediate-acting neuromuscular blocking agent, a short-acting neuromuscular blocking agent and a reversal agent proprietary to the blocking agents (collectively, the Compounds), to develop, manufacture and sell the Compounds. Recro has agreed to develop, manufacture and sell the Compounds. The Agreement calls for Recro to follow a development plan included in the Agreement unless otherwise amended or agreed to by the parties. Under the terms of the Agreement, Recro is obligated to make: (i) an upfront payment in the amount of $350,000; (ii) an annual license maintenance fee payment until the first commercial sale of a Compound; and (iii) milestone payments upon the achievement of certain milestones, up to a maximum, for each neuromuscular blocking agent, of $5 million for U.S. regulatory approval and commercialization milestones and $3 million for European regulatory approval and comercialization milestones. Recro is also obligated to pay Cornell royalties on net sales of the Compounds at a rate ranging from low to mid single digits, depending on the applicable Compound and whether there is a valid patent claim in the applicable country, subject to an annual minimum royalty amount. In addition, Recro will reimburse Cornell for past and ongoing patent costs related to prosecution and maintenance of the patents related to the Compounds. The Agreement may be terminated (i) by Recro upon 90 days' written notice, (ii) by Cornell upon Recro's material breach, subject to a cure period, and (iii) immediately by Cornell if Recro files any claim asserting the invalidity of any of Cornell's patent rights related to the Compounds. The royalty term for each Compound expires, on a country-by-country basis, on the later of (i) the expiration date of the longest-lived licensed patent, (ii) the expiration of any granted statutory period of marketing exclusivity, or (iii) the first commercial sale of a generic equivalent of the applicable Compound. On the last to expire royalty term the Agreement will automatically convert to a royalty-free nonexclusive license.

Similar Private Companies By Industry

Company Name Region
1-800-Dryclean, LLC United States
1-800-PHONESEX United States
125 Max Drycleaning Center LLC United States
180 Skills LLC United States
19Pencils, Inc. United States

Recent Private Companies Transactions

July 5, 2017
Cornell University, Novel Neuromuscular Blocking Agents

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cornell University, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at